Analyst Gil Blum of Needham maintained a Buy rating on Generation Bio, with a price target of $15.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum has given his Buy rating due to a combination of factors including Generation Bio’s recent preclinical data, which demonstrated successful delivery of siRNA to T-cells without any safety concerns. This promising development in their technology showcases the potential for effective targeting of molecules involved in T-cell mediated autoimmune diseases.
Additionally, despite the company’s decision to significantly reduce its workforce and explore strategic alternatives, Generation Bio maintains a strong cash position with $141 million on hand. This financial stability, coupled with the potential for strategic maneuvers to enhance shareholder value, supports the Buy rating, although the target price has been adjusted to reflect current uncertainties.